Anti cd138 bv421

Manufactured by BD

Anti-CD138-Bv421 is a fluorescently-labeled monoclonal antibody that targets the CD138 (Syndecan-1) cell surface antigen. This antibody is conjugated to the Brilliant Violet 421 fluorochrome.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd14 percp, by BD (1 mentions) Beckman cytoflex, by Beckman Coulter (1 mentions) Anti cd38 apc, by BD (1 mentions) Intrasure kit, by BD (1 mentions) Anti cd68 fitc, by BD (1 mentions) Facscelesta, by BD (1 mentions) Accuri c6, by BD (1 mentions) Anti cd45 bv510, by BD (1 mentions) Anti cd19 bv786, by BD (1 mentions)

Spelling variants of this product

Anti-CD138 (17 citations) CD138-BV421 (6 citations)

2 protocols using anti cd138 bv421

Phenotyping of BM Myeloid Cells in MM

Check if the same lab product or an alternative is used in the 5 most similar protocols

Collected 200 μl BM specimens from MM patients and HC, respectively. Subsequently, labeling the specimens with anti‐CD138‐Bv421, anti‐CD38‐APC, anti‐CSF1‐APC, anti‐CD14‐PerCP, anti‐CD68‐FITC, and anti‐CSF1R‐Bv421 antibodies was done (BD Biosciences). Among these, CD68 is an intracellular marker. The marker of intracellular staining was fixed and permeated with IntraSure Kit (BD Biosciences). Eventually, the data of CSF1 and CSF1R were acquired by flow cytometry (FCM) (Beckman CytoFLEX).

Zhang J., Liu Z., Cao P., Wang H., Liu H., Hua L., Xue H, & Fu R. (2022). Tumor‐associated macrophages regulate the function of cytotoxic T lymphocyte through PD‐1/PD‐L1 pathway in multiple myeloma. Cancer Medicine, 11(24), 4838-4848.

+ Open protocol

+ Expand

Multicolor Flow Cytometry for Myeloma

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry analysis for ICAM1 was performed using M10A12 (30 (link)) biotin labeled human IgG1 antibody followed by detection with Alexa-Fluor® 647-conjugated streptavidin. The non-binding YSC10 human IgG1 (34 (link),35 ) was used as the isotype control. Antibodies used to identify myeloma cells included anti-CD38-FITC, (clone AT1, Stemcell Technologies), anti-CD19-BV786 (BD), anti-CD138-BV421 (BD) and anti-CD45-BV510 (BD). Samples previously treated with daratumumab were stained for CD38 expression with multi-epitope anti-CD38-FITC (ALPCO) to prevent antigen masking. Nonspecific Fc binding was blocked with Clear Back reagent (MBL). Flow cytometry was performed on an Accuri C6 with a 96-well auto sampler (BD Biosciences) for the UCSF samples, or a FACSCelesta with a 96-well auto sampler (BD Biosciences) for the CU samples.

Sherbenou D.W., Su Y., Behrens C.R., Aftab B.T., de Acha O.P., Murnane M., Bearrows S.C., Hann B.C., Wolf J.L., Martin T.G, & Liu B. (2020). Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(22), 6028-6038.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!